Responsible Institution: China Association for Science and Technology
Sponsored by: The Chinese Pharmacological Society
Editor-in-Chief: HUANG Zhili
ISSN 1009-2501
CN 34-1206/R
WU Sheng-hua, CHEN Jing-hai, WANG Xiao-qing. Comparison on curative effect of bromocriptine treating pituitary prolactin micro-adenoma and large adenoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(8): 916-919.
[1] Wu ZB, Yu CJ, Su ZP, et al. Bromocriptine treatmentof invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up [J]. J Neurosurg, 2006, 104(1): 54-61. [2] Yin J, Su CB, Xu ZQ, et al Effectofpreoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery [J]. Chin Med Sci J, 2007, 20(1): 23-26. [3] 吴哲褒,苏志鹏,于春江.侵袭性泌乳素腺瘤溴隐亭治疗后的迟发性耐药现象: 5例报告[J].中华神经外科疾病研究杂志,2006,5(4): 367-377. [4] Becker G, Kocher M, Kortmann RD, et al. Radiation therapy in the multimodal treatment approach of pituitary adenoma[J]. Strahlenther Onkol, 2007, 178(4): 173-186. [5] Gen M,Uozumi T,Ohta M,et al. Necrotic changes in prolactinomas after long term administration of bromocriptine[J]. J Clin Endocrinol Metab,1984,59(3):463-470. [6] Ruiz-Velasco V, Tolis G. Pregnancy in hyperprolactinemic women[J]. Fertil Steril, 1984, 41(6):793-805. [7] Turlcal L. Surveillance of bromocriptine in pregnancy[J]. JAMA, 2002,247:1588-1589.